Evidence map›Paper›PMID 41394837›Full record

ArticleFrontiers in immunology2025

Rituximab for refractory ocular symptoms in myasthenia gravis with thyroid eye disease: a case report with quantitative MRI assessment.

Dingxian He, Xiangwen Li, Baitong Wang, Yaqi Wang, Chong Yan, Mengxiao Liu, Tom Hibert, Sushan Luo, Chongbo Zhao, Jianying Xi

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Dingxian He *Huashan Rare Disease Centre and Department of Neurology, Huashan Hospital, Shanghai Medical College, National Centre for Neurological Disorders, Fudan University, Shanghai, China.
Xiangwen Li *Department of Radiology, Huashan Hospital Fudan University, Shanghai, China.
Baitong WangDepartment of Encephalopathy, The Affiliated Hospital to Changchun University of Chinese Medicine, Jilin, Changchun, China.
Yaqi WangHuashan Rare Disease Centre and Department of Neurology, Huashan Hospital, Shanghai Medical College, National Centre for Neurological Disorders, Fudan University, Shanghai, China.
Chong YanHuashan Rare Disease Centre and Department of Neurology, Huashan Hospital, Shanghai Medical College, National Centre for Neurological Disorders, Fudan University, Shanghai, China.
Mengxiao LiuMagnetic Resonance (MR) Collaborations, Siemens Healthineers Ltd., Shanghai, China.
Tom HibertSwiss Innovation Hub, Siemens Healthineers International Aktiengesellschaft (AG), Lausanne, Switzerland.
Sushan LuoHuashan Rare Disease Centre and Department of Neurology, Huashan Hospital, Shanghai Medical College, National Centre for Neurological Disorders, Fudan University, Shanghai, China.
Chongbo ZhaoHuashan Rare Disease Centre and Department of Neurology, Huashan Hospital, Shanghai Medical College, National Centre for Neurological Disorders, Fudan University, Shanghai, China.
Jianying XiHuashan Rare Disease Centre and Department of Neurology, Huashan Hospital, Shanghai Medical College, National Centre for Neurological Disorders, Fudan University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aims: To report a case with concurrent myasthenia gravis (MG) and thyroid eye disease (TED) showing response to rituximab (RTX) through both clinical evaluation and quantitative MRI assessment. Methods: A 31-year-old female patient with refractory ocular symptoms from concurrent MG and TED received RTX after failing multiple conventional treatments. Treatment response was evaluated through clinical scores and quantitative T2 mapping of extraocular muscles (EOMs) before and after RTX administration. Results: Following RTX treatment, the patient achieved corticosteroid-free remission by six months post-RTX, with Myasthenia Gravis Activities of Daily Living score decreasing from 5 to 0, complete resolution of ptosis, and improvement in ocular motility and exophthalmos. Quantitative T2 mapping demonstrated significant reductions in T2 relaxation times (10.6%-20.9%) across all EOM regions of interest, with decreased standard deviations indicating restored tissue homogeneity. Conclusions: This case suggests potential therapeutic benefit of RTX for refractory ocular symptoms in concurrent MG and TED. Quantitative T2 mapping revealed pathologically elevated values that normalized post-treatment, providing preliminary objective evidence of treatment response. As a single case, the relative contributions of MG versus TED pathology cannot be definitively separated. Integrating clinical assessment with quantitative T2 mapping may offer an objective approach for monitoring treatment response in such complex dual autoimmune disorders.

Indexed as

Graves OphthalmopathyImmunologic FactorsMyasthenia GravisRituximabAdultFemaleHumansMagnetic Resonance ImagingOculomotor MusclesTreatment OutcomeImmunologic FactorsRituximabmagnetic resonance imagingmyasthenia gravisocular symptomsrituximabthyroid eye disease

Identifiers

PMID41394837
PMCPMC12695779

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.